Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Published version

Publication date

Publication license

cc-by-nc (c)  European Respiratory Society, 2019
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/184108

Pulmonary hypertension in chronic lung disease and hypoxia

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.

Citation

Citation

NATHAN, Steven D., et al. Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal. 2019. Vol. 53, num. 1, pags. 1801914. ISSN 0903-1936. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/184108

Export metadata

JSON - METS

Share record